Esperion Therapeutics (ESPR) Sees Strong Upside on Volume
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Esperion Therapeutics (NASDAQ: ESPR) is seeing sharp upside on heavy volume. Shares are up 16.5% on volume that is 6x normal. Upside could be coming amid M&A activity/valuation in the biotech space, including today's Allergan plc (NYSE: AGN) deal for Tobira Therapeutics, Inc. (NASDAQ: TBRA) at premium of up to 1650%.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BioCryst Pharma (BCRX) Shares Ramp to Session Highs Amid Upcoming Galidesivir Data Presentation
- Murphy Oil (MUR) November 30 straddle priced for movement of 10% into Q3
- Alphabet (GOOGL) call put ratio 2 calls to 1 put into Q3 and outlook as shares near record high
Create E-mail Alert Related CategoriesMomentum Movers, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!